Aquilon Pharmaceuticals SA
8.7 FTEAquilon Pharmaceuticals reported total assets of €11.1m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Jul 2026), with 8.7 full-time equivalents.
The score of Aquilon Pharmaceuticals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +459 % Total assets +42 % Headcount (avg FTE) +6 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Aquilon Pharmaceuticals's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Jul 2026
- Year ended 31 Dec 2024filed on 29 Jul 2025
- Year ended 31 Dec 2023filed on 25 Jul 2024
- Year ended 31 Dec 2022filed on 10 Jul 2023
- Year ended 31 Dec 2021filed on 02 Aug 2022
Aquilon Pharmaceuticals's financial analysis
- Solvency38.3%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Aquilon Pharmaceuticals
10 active director(s) in the register.
and 4 more
Aquilon Pharmaceuticals's shareholders and holdings →Aquilon Pharmaceuticals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0540.870.218
- VAT number
- BE0540870218
- Peppol
- Registered · 0208:0540870218 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 16 Oct 2013
- Registered office
- 4102 Seraing
- Size
- Micro · 8.7 FTE
- Latest accounts
- 2025 · filed on 22 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Aquilon Pharmaceuticals (SA) has been based in Seraing since 2013, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 444,073 € and equity of €4.25m; its revenue is not published. With 8.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 38.3%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Aquilon Pharmaceuticals
Companies in the same business, of comparable size and area, outside its group.
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- Aboleris Holdco Research and experimental development on natural sciences and engineering Charleroi · balance sheet €14.8m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
Frequently asked questions about Aquilon Pharmaceuticals
What is the revenue of Aquilon Pharmaceuticals?
Aquilon Pharmaceuticals files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Aquilon Pharmaceuticals?
In Belgium, the VAT number is the company number prefixed with BE: BE0540870218 for Aquilon Pharmaceuticals, if the company is VAT-registered. Its company number (CBE) is 0540.870.218.
Where is the registered office of Aquilon Pharmaceuticals?
According to the CBE register, the registered office of Aquilon Pharmaceuticals is in 4102 Seraing.
What is the equity of Aquilon Pharmaceuticals?
At the close of the 2025 financial year, the equity of Aquilon Pharmaceuticals amounts to 4,254,081 €, a solvency of 38.3% of total assets.
How many people work at Aquilon Pharmaceuticals?
8.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Aquilon Pharmaceuticals?
The register lists 10 active mandates at Aquilon Pharmaceuticals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Aquilon Pharmaceuticals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →